LI
PDLI

Leap Investments’s PDL BioPharma, Inc. PDLI Stock Holding History

Leap Investments’s Portfolio PDLI Stock Details PDLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-69,496
Closed -$150K – 689
2019
Q3 		$150K Buy
+69,496
New +$186K 0.07% 334

Other funds holding PDLI

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
ECM
Engine Capital Management New York $1.03B AUM 4.33% 1-Year Est. Return
Brandes Investment Partners
Brandes Investment Partners La Jolla, California $14.3B AUM 23.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $860B AUM 41.15% 1-Year Est. Return
Connor, Clark & Lunn Investment Management (CC&L)
Connor, Clark & Lunn Investment Management (CC&L) Vancouver, British Columbia, Canada $52.8B AUM 58.98% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $751B AUM 38.74% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Leap Investments's PDLI Position: Q4 2019 in Review

Leap Investments sold out of PDL BioPharma, Inc. (PDLI) in Q4 2019, closing a stake of 69,496 shares — an estimated $150K sold.

Leap Investments first reported a position in PDLI in Q3 2019 and held it in 1 quarter. The position peaked at $150K in Q3 2019. 150 funds tracked by Wall St. Rank hold PDLI as of Q4 2019.

  • Leap Investments reported no remaining PDL BioPharma, Inc. position as of Q4 2019 after selling out during the quarter.
  • Leap Investments sold 69,496 PDL BioPharma, Inc. shares in Q4 2019, an estimated $150K.
  • Leap Investments first reported a position in PDL BioPharma, Inc. in Q3 2019 and held it in 1 quarter.
  • Leap Investments's PDL BioPharma, Inc. position peaked at $150K in Q3 2019.
  • 150 funds tracked by Wall St. Rank held PDL BioPharma, Inc. as of Q4 2019.

Based on Leap Investments's 13F filing for Q4 2019, filed 14 Feb 2020.